Biomerica's inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal

Core Insights - Biomerica, Inc. has announced that its inFoods® IBS blood test can significantly alleviate abdominal pain in patients with Irritable Bowel Syndrome (IBS) through a personalized dietary therapy [1][5][10] Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products, particularly for gastrointestinal and inflammatory diseases [13] Product Details - The inFoods® IBS test identifies specific foods that trigger elevated Immunoglobulin G (IgG) antibody responses, which are linked to IBS symptoms, with a 95% confidence interval for accuracy [2][5] - The test is unique in its technology, specifically designed for IBS patients, and aims to provide personalized dietary recommendations [2][7] Clinical Trial Findings - A randomized, double-blind, placebo-controlled trial involving 238 IBS patients showed that 59.6% of those following a personalized elimination diet based on the inFoods test met FDA standards for abdominal pain reduction, compared to 42.2% in the control group [5] - The benefits were particularly notable in patients with constipation-predominant IBS (IBS-C) and mixed IBS (IBS-M), with 67.1% and 66% respectively meeting the FDA target for pain reduction [5][12] Market Context - IBS affects approximately 10% to 15% of adults in the U.S., significantly impacting quality of life and work productivity [3] - Current IBS treatments often involve restrictive diets or pharmaceuticals, whereas the inFoods® IBS test allows for a more targeted approach by identifying only a few specific trigger foods [10][11]